Legend Biotech Corporation (FRA:9LB)

Market Cap	2.84B -57.3%
Revenue (ttm)	774.78M +74.8%
Net Income	-204.30M
EPS	-1.11
Shares Out	n/a
PE Ratio	n/a
Forward PE	90.51
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	379
Open	15.50
Previous Close	15.40
Day's Range	15.20 - 15.50
52-Week Range	13.80 - 38.00
Beta	n/a
RSI	43.32
Earnings Date	Mar 11, 2026

About Legend Biotech

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgk...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 2,900
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9LB

Financial Performance

In 2024, Legend Biotech's revenue was $627.24 million, an increase of 119.97% compared to the previous year's $285.14 million. Losses were -$177.03 million, -65.84% less than in 2023.

Financial numbers in USD